Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of Three Doses of Orvepitant in Subjects With Chronic Refractory Cough

Next Previous
Trial Profile

A Double-Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of Three Doses of Orvepitant in Subjects With Chronic Refractory Cough

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orvepitant (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Acronyms VOLCANO-2
  • Sponsors NeRRe Therapeutics

    • Most Recent Events

    • 06 Jun 2019 Primary endpoint (Change from Baseline to Week 12 in awake objective cough frequency measured with an automated cough monitor (ACM), the Vitalojak: Orvepitant vs Placebo) has not been met, according to a NeRRe Therapeutics media release.
    • 06 Jun 2019 According to a NeRRe Therapeutics media release, data from this trial data will be presented in full at a forthcoming international scientific meeting.
    • 06 Jun 2019 According to a NeRRe Therapeutics media release, this study outcomes support further development of orvepitant in refractory chronic cough and the company intend to meet with the FDA and the EMA during Q4 this year to discuss next steps.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top